Marker that predicts cell death in kidneys identified

When the kidneys are damaged—after surgery, cardiac arrest, or as a side effect of certain medications—doctors often face one ...
Targeted Oncology

Perioperative Disitamab Vedotin/Tislelizumab Shows Promise in High-Risk UTUC

1. Huang J. Disitamab vedotin plus tislelizumab as nephron-sparing therapy for high-risk upper tract urothelial carcinoma: The phase II DISTINCT-I trial. Presented at: ESMO 2025 Congress; October ...
EurekAlert!

Researchers identify marker that predicts cell death in kidneys

Researchers from Aarhus University have discovered a protein that can predict whether kidney cells will survive or die after acute injury. The finding could pave the way for new treatments and benefit ...
Le Lézard

Nefecon Included in the Updated KDIGO Clinical Practice Guideline, Strengthening Asahi Kasei's Position in IgA Nephropathy Treatment

Asahi Kasei, a global provider of healthcare and pharmaceutical solutions, announced that Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules), has been included ...
Yahoo Finance

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

As part of the transaction, Chugai will gain exclusive rights to develop and commercialize sparsentan in Japan, South Korea and Taiwan. On September 26, 2025, CSL Vifor and Travere announced support ...